- Life Sciences - 10:00 Predicting people’s ’brain age’ could help to spot who is at risk of early death
- Medicine - 10:00 Six ways Imperial researchers are working to eliminate malaria
- Business - 08:00 Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
- Social Sciences - Apr 24 Prenatal screening for Down’s syndrome seen as ‘routine practice’
- Medicine - Apr 24 Family caregivers help with wider range of healthcare tasks than thought
- Medicine - Apr 24 Electrical engineer puts sweat tech to the test
- Medicine - Apr 24 Yale‘s Dr. Patrick O’Connor partners with experts to address TV portrayals of addiction
- Medicine - Apr 24 Tiny ‘cages’ to keep vaccine supplies safe
- Medicine - Apr 24 Novartis real- world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
- Medicine - Apr 24 Novartis expands global collaboration with Amgen to commercialize first-in- class AMG 334 (erenumab) program in migraine prevention in the US and Canada
- Medicine - Apr 24 ’In the Moment’ at TEDxStanford
- Medicine - Apr 24 Ideas sought for long- range planning process
- Environment - Apr 21 Earth day: Imperial event brings together experts to tackle air pollution
- Medicine - Apr 21 Yale experts offer thoughts on ‘Science Under Siege’
- Life Sciences - Apr 21 NIH Awards Team $7 Million for Autism Genetics Research
- Medicine - Apr 21 Senior salsa brings home the power of staying active
Defeating dementia in Down’s syndrome
A £1m brain-imaging study has just been launched at the University of Cambridge to investigate why people with Down’s syndrome (DS) are at such high risk of Alzheimer’s disease.
Almost 100% of people with Down’s Syndrome develop pathological signs of Alzheimer’s, and clinical symptoms are seen in Down’s Syndrome around 40 years earlier than in the general population"—Professor Tony Holland
There are 700,000 cases of dementia in the UK, costing £17 billion a year, and these figures are predicted to rise with the ageing population. Besides the rare familial forms of Alzheimer’s, DS is the only known disorder in which one can so clearly expect early-onset dementia to develop.
Professor Tony Holland, of the Cambridge Intellectual and Developmental Disabilities Research Group, who is leading the research, said: "Almost 100% of people with DS develop pathological signs of Alzheimer’s, and clinical symptoms are seen in DS around 40 years earlier than in the general population."
The research team is looking for individuals with DS to volunteer to take part in the study. The team has produced a short film – www.youtube.com/user/downsproject – to explain the testing process.
"People with DS are living longer lives, and better lives, but this can be a poisoned chalice, as with this comes a real risk of Alzheimer’s," said Professor Holland. “Now we need volunteers to come forward to help us explore what is happening to the brain."
This four-year study aims to determine the role of beta amyloid, a key factor in causing Alzheimer’s. People with DS may be more vulnerable to this type of dementia as they have more amyloid in their brains (a key amyloid gene is located on chromosome 21, which is triplicated in people with DS). Investigating amyloid in this way will also help understand Alzheimer’s development in the general population.
The term ‘dementia’ describes a set of symptoms which can include loss of memory, mood changes, and problems with communication and reasoning. As the disease progresses, people with Alzheimer’s need more support from those who care for them. Eventually, they need help with all their daily activities.
If you have Down’s syndrome or know someone with Down’s syndrome over the age of 30, who might be interested to hear more about this study, please either Tiina or Liam by email on the details below.
Tiina: ta337 [a] medschl.cam.ac (p) uk
Liam: lrw34 [a] medschl.cam.ac (p) uk
Telephone: 01223 746127 (voice mail after office hours)
Last job offers
- Medicine/Pharmacology - 18.4
Professeur-e ordinaire ou associé-e, médecin-chef-fe du service de médecine interne de réhabilitation...
- Chemistry - 18.4
Doktorand/in Funktionelle Materialien
- Medicine/Pharmacology - 15.4
Chargé-e de cours à 40% dans le domaine neuro-musculaire
- Life Sciences - 15.4
Wissenschaftliche/r Mitarbeiter/in 60%
- Environment - 21.3
Leiter/in der Forschungsgruppe Vegetationsökologie
- Medicine/Pharmacology - 21.3
Dozentin / Dozenten für Pharmakologie und Pharmatechnologie mit Fachgruppenleitung
- Life Sciences - 24.4
Lecturer, Microbiology, School of Science and Health
- Medicine/Pharmacology - 24.4
899615 Clinical Professor of Cardiology